What is Tandem Diabetes Care's market cap?

Tandem Diabetes Care (TNDM) has a market capitalization of $1.2B and trades on NASDAQ.

What is Tandem Diabetes Care's revenue and profitability?

Tandem Diabetes Care generated $1.0B in trailing twelve-month revenue with a net loss of $94.5M, representing a net margin of -9.2%. Gross margin stands at 54.9%, with free cash flow of -$24.5M. These figures are based on the Q1 2026 filing.

Who are Tandem Diabetes Care's competitors?

Tandem Diabetes Care's key competitors include Insulet, Medtronic, Abbott Laboratories, and others. These companies compete in similar markets and product categories.

Who does Tandem Diabetes Care partner with?

Tandem Diabetes Care's notable partners include Dexcom, Abbott.

Where is Tandem Diabetes Care headquartered?

Tandem Diabetes Care is headquartered in United States of America and employs approximately 2,400 people. It has been publicly traded since 2013.

Tandem Diabetes Care

TNDM

Tandem Diabetes Care is a global medical technology company focused on the design, development, and commercialization of advanced insulin delivery systems.

Market cap

$1.18B+6.0%

Revenue$1.0B+4.5%

Net income-$94.5M+48.6%

Free cash flow-$24.5M-62.7%

EPS (diluted)-$1.40+49.6%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$247.2MBeat by $6.8M EPS-$0.30Beat by $0.16

Read the full report

Next report

Aug 6, 2026 (In 1 week)

Revenue estimate$255.0M

EPS estimate-$0.34

Financials

Q1 2026

Income statement

See full

Revenue$247.2M+5.5%

Gross profit$136.8M+15.5%

Operating income-$17.4M+85.6%

Net income-$20.4M+84.4%

EPS (diluted)-$0.30+84.8%

Balance sheet

See full

Cash & equivalents$179.3M+235%

Total debt$734.7M+49.0%

Total equity$132.4M-14.7%

Total assets$1.2B+25.1%

Cash flow

See full

Operating cash flow$11.1M+160%

CapEx$6.3M+111%

Free cash flow$4.8M+123%

Valuation & ratios

Valuation

See full

Market cap$1.18B+6.0%

Enterprise value$1.73B+15.0%

P/S1.2×0.0×

Profitability

See full

Gross margin54.9%+2.7pp

Operating margin-8.2%-2.9pp

Net margin-9.2%-3.1pp

Returns & leverage

See full

Return on equity-65.7%-14.7pp

Debt / equity5.5×+2.4×

Current ratio3.6×+1.3×

Segments

By product

See full

Supplies and other$136.8M+3.4%

Pump$110.4M+8.1%

Competitors

By market cap

Abbott$182.00B-17.2%

Medtronic$107.81B-8.5%

Insulet$11.4B-44.4%

Tandem Diabetes Care$1.2B+4.9%

Beta Bionics, Inc.$712.5M+17.5%

Embecta Corp.$203.8M-69.2%

InfuSystem Holdings$188.9M+52.6%

Modular Medical$12.5M-67.1%

By revenue growth

Beta Bionics, Inc.+52.5%

Insulet+31.9%

Medtronic+8.4%

Abbott+8.1%

Tandem Diabetes Care+4.5%

InfuSystem Holdings+3.5%

Embecta Corp.-3.4%

By net margin

Medtronic13.2%-0.7pp

Abbott11.65%-20.8pp

Embecta Corp.10.73%+5.8pp

Insulet10.44%-7.9pp

InfuSystem Holdings5.56%+3.2pp

Tandem Diabetes Care-9.2%+9.5pp

Beta Bionics, Inc.-61.32%+32.7pp

Profile

Tandem Diabetes Care is a global medical technology company focused on the design, development, and commercialization of advanced insulin delivery systems. The company provides intelligent pump platforms and integrated software solutions aimed at reducing the daily burden of diabetes management for patients worldwide.

Competitive position

A leading provider of automated insulin delivery systems known for advanced hybrid closed-loop technology and user-centric design.

GeographiesUnited States, International

Customer segmentsType 1 diabetes patients, Insulin-intensive Type 2 diabetes patients

Business modelMedical device manufacturing, Razor-and-blade (hardware and recurring consumables)

SuppliersElectronic component manufacturers, Specialized medical-grade plastics suppliers, Software developers

CustomersDurable medical equipment (DME) distributors, Pharmacies, Direct-to-patient sales

CountryUnited States of America

Listed2013

Employees2.4K

CEOJohn F. Sheridan

SectorHealthcare

IndustryMedical - Devices

Websitetandemdiabetes.com

FilingsSEC EDGAR

Ask your AI about Tandem Diabetes Care.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Tandem Diabetes Care's market cap?: Tandem Diabetes Care (TNDM) has a market capitalization of $1.2B and trades on NASDAQ.
What is Tandem Diabetes Care's revenue and profitability?: Tandem Diabetes Care generated $1.0B in trailing twelve-month revenue with a net loss of $94.5M, representing a net margin of -9.2%. Gross margin stands at 54.9%, with free cash flow of -$24.5M. These figures are based on the Q1 2026 filing.
Who are Tandem Diabetes Care's competitors?: Tandem Diabetes Care's key competitors include Insulet, Medtronic, Abbott Laboratories, and others. These companies compete in similar markets and product categories.
Who does Tandem Diabetes Care partner with?: Tandem Diabetes Care's notable partners include Dexcom, Abbott.
Where is Tandem Diabetes Care headquartered?: Tandem Diabetes Care is headquartered in United States of America and employs approximately 2,400 people. It has been publicly traded since 2013.